What must be said April 21st

Quote

Anonymous

Guest
1) Dividend (and not a cheap one, please)
2) Succession plans (details, please)
3) How company will grow beyond current products (smart buy-outs, please)
4) Dmab and XGEVA are doing great (surprise us, please)

Please, please, please, give the shareholders what they've been begging for! You must do it!
 






Anonymous said:
1) Dividend (and not a cheap one, please)
2) Succession plans (details, please)
3) How company will grow beyond current products (smart buy-outs, please)
4) Dmab and XGEVA are doing great (surprise us, please)

Please, please, please, give the shareholders what they've been begging for! You must do it!
Click to expand...


The analysts, fund managers and institutional heads are calling for a first ever dividend. There is a huge well spring demanding a dividend. There is absolutely no reason not to declare a regular one. If Kevin and bored (sp. on purpose) don't come up with one, all believability is out the window and his (Kevin) management skills, as well. Loss of credibility comes to mind. Do the shareholder good and make us feel proud.
 






Do the executives think an expansion into Brazil deserves a press release?

The street wants to see real and aggressive expansion of revenue.

What's next...a press release announcing they are launching Nplate into Iceland?
Small fish...
 












Brazil allows Amgen to control distribution and enter biosimilars, small and wise. The company has nobody with any 'real' background on how to lead global expansion. Those at the top with the exception of maybe BB and JP have little if any reason to be in the position they are in...there at Amgen because they failed elsewhere. So, whilst Brazil may be "small fish", Amgen has to start small because anything large will inevitably be screwed up.
 






Anonymous said:
Brazil allows Amgen to control distribution and enter biosimilars, small and wise. The company has nobody with any 'real' background on how to lead global expansion. Those at the top with the exception of maybe BB and JP have little if any reason to be in the position they are in...there at Amgen because they failed elsewhere. So, whilst Brazil may be "small fish", Amgen has to start small because anything large will inevitably be screwed up.
Click to expand...

Then isn't it time the CEO and staff turn the keys over to the seasoned professionals in this business?
 












Top Bottom
Back
Quote